Drug Development

SBP-101

SBP-101 is a proprietary polyamine licensed by Sun BioPharma, Inc. from the University of Florida in 2011.  SunBioPharma, Inc. intends to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. View our presentation (.pdf) »

SBP-102

SBP-102 is currently in non-clinical feasibility evaluation for the treatment of patients with pancreatitis.

SBP-103

SBP-103 is currently in non-clinical exploratory evaluation.

Clinical Trials

The First-Time-in-Human Phase 1 study of SBP-101 in patients with pancreatic ductal adenocarcinoma is currently enrolling in Australia and the United States.  A dose-escalation phase is expected to precede an expansion phase at the Maximum Tolerated Dose.

Click here for more information regarding enrollment in the First-Time-in-Human Phase 1 study of SBP-101 in Australia.

Click here for more information regarding enrollment in the First-Time-in-Human Phase 1 study of SBP-101 in the United States.